These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 19177065)

  • 1. Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies.
    Muller PY; Brennan FR
    Clin Pharmacol Ther; 2009 Mar; 85(3):247-58. PubMed ID: 19177065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies.
    Muller PY; Milton M; Lloyd P; Sims J; Brennan FR
    Curr Opin Biotechnol; 2009 Dec; 20(6):722-9. PubMed ID: 19896825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases.
    Brennan FR; Cauvin A; Tibbitts J; Wolfreys A
    Drug Dev Res; 2014 May; 75(3):115-61. PubMed ID: 24782266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticals.
    Buckley LA; Chapman K; Burns-Naas LA; Todd MD; Martin PL; Lansita JA
    Int J Toxicol; 2011 Oct; 30(5):583-90. PubMed ID: 22013138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical safety evaluation of monoclonal antibodies.
    Lynch CM; Grewal IS
    Handb Exp Pharmacol; 2008; (181):19-44. PubMed ID: 18071940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.
    Lowe PJ; Tannenbaum S; Wu K; Lloyd P; Sims J
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):195-209. PubMed ID: 20050847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies.
    Brennan FR; Morton LD; Spindeldreher S; Kiessling A; Allenspach R; Hey A; Muller PY; Frings W; Sims J
    MAbs; 2010; 2(3):233-55. PubMed ID: 20421713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical approaches to dose selection for first-in-human clinical trials with novel biopharmaceuticals.
    Tibbitts J; Cavagnaro JA; Haller CA; Marafino B; Andrews PA; Sullivan JT
    Regul Toxicol Pharmacol; 2010 Nov; 58(2):243-51. PubMed ID: 20558225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro assays supporting the safety assessment of immunomodulatory monoclonal antibodies.
    Brennan FR; Kiessling A
    Toxicol In Vitro; 2017 Dec; 45(Pt 3):296-308. PubMed ID: 28263892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toward experimental assessment of receptor occupancy: TGN1412 revisited.
    Waibler Z; Sender LY; Kamp C; Müller-Berghaus J; Liedert B; Schneider CK; Löwer J; Kalinke U
    J Allergy Clin Immunol; 2008 Nov; 122(5):890-2. PubMed ID: 18805577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunostimulatory antibodies: challenging the drug testing paradigm.
    Bhogal N; Combes R
    Toxicol In Vitro; 2007 Oct; 21(7):1227-32. PubMed ID: 17434714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical and clinical safety of monoclonal antibodies.
    Tabrizi MA; Roskos LK
    Drug Discov Today; 2007 Jul; 12(13-14):540-7. PubMed ID: 17631248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of biologics, lessons learnt from TGN1412.
    Stebbings R; Poole S; Thorpe R
    Curr Opin Biotechnol; 2009 Dec; 20(6):673-7. PubMed ID: 19892543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials.
    Wang DD; Zhang S; Zhao H; Men AY; Parivar K
    J Clin Pharmacol; 2009 Sep; 49(9):1012-24. PubMed ID: 19620385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative requirements for exploratory clinical trials -- eIND, eCTA and microdosing.
    Muller PY
    Adv Drug Deliv Rev; 2011 Jun; 63(7):511-7. PubMed ID: 21034787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hazard identification and risk assessment for biologics targeting the immune system.
    Weir AB
    J Immunotoxicol; 2008 Jan; 5(1):3-10. PubMed ID: 18382852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical efficacy and safety models for mAbs: the challenge of developing effective model systems.
    Dixit R; Coats S
    IDrugs; 2009 Feb; 12(2):103-8. PubMed ID: 19204884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development.
    Mascelli MA; Zhou H; Sweet R; Getsy J; Davis HM; Graham M; Abernethy D
    J Clin Pharmacol; 2007 May; 47(5):553-65. PubMed ID: 17379759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data.
    Vcelar B; Stiegler G; Wolf HM; Muntean W; Leschnik B; Mehandru S; Markowitz M; Armbruster C; Kunert R; Eibl MM; Katinger H
    AIDS; 2007 Oct; 21(16):2161-70. PubMed ID: 18090042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A brief survey of first-in-human studies.
    Wexler D; Bertelsen KM
    J Clin Pharmacol; 2011 Jul; 51(7):988-93. PubMed ID: 20671293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.